Synkrino Development

Synkrino Development Company (SDC) partners with biotech to finance and develop innovative high impact therapeutics programs. We serve the entire pharma ecosystem of patients, prescribers, payers, biotechs, and pharma companies by financing, accelerating, and pushing forward drug candidates with the potential to significantly improve the standard of care – offering a new range of therapeutic options that balance price and treatment outcome. Our process creates portfolios of orthogonal assets (biological target, disease indication, modality) with the aim of de-risking biotech investments for institutional investors. We partner with biotech on an asset basis – not a company basis – creating a stream of uncorrelated cash flows with a superior return-on-investment profile.